RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Est. Return
25.98%
1 Year Est. Return
+25.98%
AUM
$1.6B
AUM Growth
-$143M
(-8.2%)
Holding
105
Top Buys
| 1 | +$21.5M | |
| 2 | +$21.2M | |
| 3 | +$16.8M | |
| 4 |
SPDR S&P Biotech ETF
XBI
|
+$12.6M |
| 5 |
Arcellx
ACLX
|
+$12.3M |
Top Sells
| 1 | +$105M | |
| 2 | +$25.5M | |
| 3 | +$23.9M | |
| 4 |
Legend Biotech
LEGN
|
+$17.4M |
| 5 |
UnitedHealth
UNH
|
+$15.6M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$50.1B
| $96.9M | 6.04% |
175,750
|
|
||
2
Eli Lilly
LLY
$741B
| $90.8M | 5.66% |
116,500
+3,000
|
|
||
3
Merus
MRUS
$7.19B
| $55.9M | 3.49% |
1,063,608
+82,857
|
|
||
4
Rhythm Pharmaceuticals
RYTM
$6.99B
| $54.4M | 3.39% |
861,153
+26,965
|
|
||
5
Insmed
INSM
$34.1B
| $52.8M | 3.29% |
525,000
+9,100
|
|
||
6
Ultragenyx Pharmaceutical
RARE
$3.05B
| $50.6M | 3.15% |
1,391,072
-3,362
|
|
||
7
Revolution Medicines
RVMD
$8.88B
| $49M | 3.05% |
1,330,960
+49,320
|
|
||
8
Intuitive Surgical
ISRG
$156B
| $44.6M | 2.78% |
82,000
-20,000
|
|
||
9
Madrigal Pharmaceuticals
MDGL
$9.66B
| $42.5M | 2.65% |
140,296
-26,402
|
|
||
10
Mirum Pharmaceuticals
MIRM
$3.83B
| $41.6M | 2.59% |
818,206
-133,559
|
|
||
11
Boston Scientific
BSX
$145B
| $38.1M | 2.38% |
355,000
+78,000
|
|
||
12
Ascendis Pharma
ASND
$12.5B
| $37.5M | 2.33% |
217,000
+1,000
|
|
||
13
iRhythm Technologies
IRTC
$5.64B
| $37.3M | 2.33% |
242,500
-11,800
|
|
||
14
Akero Therapeutics
AKRO
$4.31B
| $34.2M | 2.13% |
640,526
-32,233
|
|
||
15
Penumbra
PEN
$9.85B
| $33M | 2.05% |
128,500
-42,500
|
|
||
16
Agios Pharmaceuticals
AGIO
$2.34B
| $32.9M | 2.05% |
989,745
+647,565
|
|
||
17
Alnylam Pharmaceuticals
ALNY
$61.5B
| $32.6M | 2.03% |
100,000
-43,250
|
|
||
18
Evolent Health
EVH
$894M
| $31.8M | 1.98% |
2,820,700
+125,000
|
|
||
19
Zai Lab
ZLAB
$3.27B
| $30.5M | 1.9% |
871,392
-33,200
|
|
||
20
Exact Sciences
EXAS
$11.5B
| $30.4M | 1.89% |
572,000
+92,000
|
|
||
21
Xenon Pharmaceuticals
XENE
$3.23B
| $29.2M | 1.82% |
931,681
|
|
||
22
Travere Therapeutics
TVTX
$2.33B
| $28.2M | 1.76% |
1,908,208
-1,012,988
|
|
||
23
Scholar Rock
SRRK
$3.07B
| $28.1M | 1.75% |
794,133
+32,592
|
|
||
24
DexCom
DXCM
$26B
| $25M | 1.56% |
286,750
-110,900
|
|
||
25
Phreesia
PHR
$1.37B
| $23.8M | 1.48% |
837,300
-311,036
|
|